<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LASTACAFT - alcaftadine solution/ drops </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LASTACAFT™ safely and effectively. See full prescribing information for LASTACAFT™.<br><br>LASTACAFT™ (alcaftadine ophthalmic solution) 0.25%<br>Initial U.S. Approval: 2010
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta"><span class="Bold">LASTACAFT™</span> is an H<span class="Sub">1</span> histamine receptor antagonist indicated for the prevention of <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> associated with <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>. (<a href="#s1">1</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Instill one drop in each eye once daily. (<a href="#s2">2</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Ophthalmic solution containing alcaftadine, 0.25% (2.5 mg/mL) (<a href="#s3">3</a>)
 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>To minimize the risk of contamination, do not touch dropper tip to any surface. Keep bottle tightly closed when not in use. (<a href="#s6">5.1</a>)
</li>
<li>
<span class="Bold">LASTACAFT™</span> should not be used to treat contact lens-related irritation. (<a href="#s7">5.2</a>)
</li>
<li>Remove contact lenses prior to instillation of <span class="Bold">LASTACAFT™</span>. (<a href="#s7">5.2</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common ocular adverse reactions, occurring in &lt; 4% of <span class="Bold">LASTACAFT™</span>-treated eyes, were <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, burning and/or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> on instillation, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">eye redness</span>, and <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye pruritus</span>. (<a href="#s10">6.1</a>)
 </p>
<p class="Highlighta">The most common non-ocular adverse reactions, occurring in &lt; 3% of subjects with <span class="Bold">LASTACAFT™-</span>treated eyes, were <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>. (<a href="#s11">6.2</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-433-8871 or FDA at 1-800-FDA-1088 or
</span><span class="Bold">www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Contamination of Tip and Solution
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Contact Lens Use
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Topical Ophthalmic Use Only
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Ocular Adverse Reactions
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Non-ocular Adverse Reactions
</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use
</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-9.2" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES
</a></h1>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<h2><a href="#section-13.1" class="toc">17.1 <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Sterility</span> of Dropper Tip
</a></h2>
<h2><a href="#section-13.2" class="toc">17.2 Concomitant Use of Contact Lenses
</a></h2>
<h2><a href="#section-13.3" class="toc">17.3 Topical Ophthalmic Use only
</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First"><span class="Bold">LASTACAFT™</span> is an H<span class="Sub">1</span> histamine receptor antagonist indicated for the prevention of <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> associated with <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Instill one drop in each eye once daily.
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Topical ophthalmic solution containing alcaftadine, 0.25% (2.5 mg/mL).
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<p class="First">None.
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Contamination of Tip and Solution
</h2>
<p class="First">To minimize contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Contact Lens Use
</h2>
<p class="First">Patients should be advised not to wear a contact lens if their eye is red. <span class="Bold">LASTACAFT™</span> should not be used to treat contact lens-related irritation.
</p>
<p><span class="Bold">LASTACAFT™</span> should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of <span class="Bold">LASTACAFT™</span>. The preservative in <span class="Bold">LASTACAFT™</span>, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of <span class="Bold">LASTACAFT™</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Topical Ophthalmic Use Only
</h2>
<p class="First"><span class="Bold">LASTACAFT™</span> is for topical ophthalmic use only.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s9"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Ocular Adverse Reactions
</h2>
<p class="First">The most frequent ocular adverse reactions, occurring in &lt; 4% of <span class="Bold">LASTACAFT™</span>-treated eyes, were <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, burning and/or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> upon instillation, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">eye redness</span> and <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye pruritus</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Non-ocular Adverse Reactions
</h2>
<p class="First">The most frequent non-ocular adverse reactions, occurring in &lt; 3% of subjects with <span class="Bold">LASTACAFT™</span>-treated eyes, were <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>. Some of these events were similar to the underlying disease being studied.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s12"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s13"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<p class="First">Pregnancy Category B. Reproduction studies performed in rats and rabbits revealed no evidence of impaired female reproduction or harm to the fetus due to alcaftadine. Oral doses in rats and rabbits of 20 and 80 mg/kg/day, respectively, produced plasma exposure levels approximately 200 and 9000 times the plasma exposure at the recommended human ocular dose. There are however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s14"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when <span class="Bold">LASTACAFT™</span> is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s15"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 2 years have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s16"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">No overall differences in safety or effectiveness were observed between elderly and younger subjects.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s17"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First"><span class="Bold">LASTACAFT™</span> is a sterile, topically administered H<span class="Sub">1</span> receptor antagonist containing alcaftadine for ophthalmic use.
</p>
<p>Alcaftadine is a white to yellow powder with an empirical formula of C<span class="Sub">19</span>H<span class="Sub">21</span>N<span class="Sub">3</span>O and a molecular weight of 307.39.
</p>
<p><span class="Bold">Contains: Active:</span> alcaftadine 0.25% (2.5 mg/mL). <span class="Bold">Preservative:</span> benzalkonium chloride 0.005%. <span class="Bold">Inactives:</span> edetate disodium, monobasic sodium phosphate, purified water, sodium chloride, sodium hydroxide and/or hydrochloric acid to adjust pH
</p>
<p><span class="Bold">Chemical Name:</span> 6,11-dihydro-11-(1-methyl-4-piperidinylidene)-5<span class="Italics">H</span>-imidazo[2,1-b] [3] benzazepine-3-carboxaldehyde
</p>
<p><span class="Bold">Structural Formula:</span></p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c192fecc-046d-4905-868f-b8200320309c&amp;name=las00-0000-01.jpg">
</div>
<p>The drug product has a pH of approximately 7 and an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of approximately 290 mOsm/kg.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s18"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s19"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">Alcaftadine is a H<span class="Sub">1</span> histamine receptor antagonist and inhibitor of the release of histamine from mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s20"></a><a name="section-9.2"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-9.2.1"></a><p></p>
<p class="First"><span class="Italics">Absorption</span></p>
<p>Following bilateral topical ocular administration of alcaftadine ophthalmic solution, 0.25%, the mean plasma C<span class="Sub">max</span> of alcaftadine was approximately 60 pg/mL and the median T<span class="Sub">max</span> occurred at 15 minutes. Plasma concentrations of alcaftadine were below the lower limit of quantification (10 pg/mL) by 3 hours after dosing. The mean C<span class="Sub">max</span> of the active carboxylic acid metabolite was approximately 3 ng/mL and occurred at 1 hour after dosing. Plasma concentrations of the carboxylic acid metabolite were below the lower limit of quantification (100 pg/mL) by 12 hours after dosing. There was no indication of systemic accumulation or changes in plasma exposure of alcaftadine or the active metabolite following daily topical ocular administration.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-9.2.2"></a><p></p>
<p class="First"><span class="Italics">Distribution</span></p>
<p>The protein binding of alcaftadine and the active metabolite are 39.2% and 62.7%, respectively.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-9.2.3"></a><p></p>
<p class="First"><span class="Italics">Metabolism</span></p>
<p>The metabolism of alcaftadine is mediated by non-CYP450 cytosolic enzymes to the active carboxylic acid metabolite.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-9.2.4"></a><p></p>
<p class="First"><span class="Italics">Excretion</span></p>
<p>The elimination half-life of the carboxylic acid metabolite is approximately 2 hours following topical ocular administration. Based on data following oral administration of alcaftadine, the carboxylic acid metabolite is primarily eliminated unchanged in the urine.
</p>
<p>In vitro studies showed that neither alcaftadine nor the carboxylic acid metabolite substantially inhibited reactions catalyzed by major CYP450 enzymes.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s25"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s26"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Alcaftadine was not mutagenic or genotoxic in the Ames test, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay or the mouse micronucleus assay.
</p>
<p>Alcaftadine was found to have no effect on fertility of male and female rats at oral doses up to 20 mg/kg/day (approximately 200 times the plasma exposure at the recommended human ocular dose).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s27"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<p class="First">Clinical efficacy was evaluated in conjunctival allergen challenge (CAC) studies. <span class="Bold">LASTACAFT™</span> was more effective than its vehicle in preventing <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">ocular itching</span> in patients with <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span> induced by an ocular allergen challenge, both at 3 minutes post-dosing and at 16 hours post-dosing of <span class="Bold">LASTACAFT™</span>.
</p>
<p>The safety of <span class="Bold">LASTACAFT™</span> was evaluated in a randomized clinical study of 909 subjects over a period of 6 weeks.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s28"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First"><span class="Bold">LASTACAFT™</span> (alcaftadine ophthalmic solution) 0.25% is supplied in an opaque, white low-density polyethylene bottle with a white polypropylene cap.
</p>
<p>3 mL fill in 5 mL bottle      NDC 54868-6294-0<br></p>
<div class="Section" data-sectionCode="44425-7">
<a name="e28"></a><a name="section-12.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span> Store at 15-25°C (59-77°F).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s29"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-13.1"></a><p></p>
<h2>17.1 <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Sterility</span> of Dropper Tip
</h2>
<p class="First">Patients should be advised to not touch dropper tip to any surface, as this may contaminate the contents.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-13.2"></a><p></p>
<h2>17.2 Concomitant Use of Contact Lenses
</h2>
<p class="First">Patients should be advised not to wear a contact lens if their eye is red. Patients should be advised that <span class="Bold">LASTACAFT™</span> should not be used to treat contact lens-related irritation. Patients should also be advised to remove contact lenses prior to instillation of <span class="Bold">LASTACAFT™</span>. The preservative in <span class="Bold">LASTACAFT™</span>, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of <span class="Bold">LASTACAFT™</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-13.3"></a><p></p>
<h2>17.3 Topical Ophthalmic Use only
</h2>
<p class="First">For topical ophthalmic administration only.
</p>
<p><span class="Bold">ALLERGAN<br></span>Manufactured for Allergan, Inc., Irvine, CA 92612, U.S.A.<br>© 2010 Allergan, Inc.<br>® and ™ marks owned by Allergan, Inc.<br>Manufactured in the U.S.A. by JHP Pharmaceuticals, LLC
</p>
<p>72409US10B
</p>
<p><span class="Bold">Relabeling and Repackaging by:<br></span>Physicians Total Care, Inc., Tulsa, OK    74146
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s33"></a><a name="section-14"></a><p></p>
<p class="First"><br></p>
<p><span class="Bold">NDC 54868-6294-0</span></p>
<p><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c192fecc-046d-4905-868f-b8200320309c&amp;name=6294.jpg"></p>
<p><span class="Bold">LASTACAFT™</span></p>
<p>(alcaftadine ophthalmic
</p>
<p>solution) 0.25%
</p>
<p><span class="Bold">3 mL</span> Sterile
</p>
<p><span class="Bold"><br></span></p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LASTACAFT 		
					</strong><br><span class="contentTableReg">alcaftadine solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6294(NDC:0023-4290)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>alcaftadine</strong> (alcaftadine) </td>
<td class="formItem">alcaftadine</td>
<td class="formItem">2.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, monobasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6294-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022134</td>
<td class="formItem">08/19/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9fd799f7-9bd7-40c6-b003-d27ca9cb0f10</div>
<div>Set id: c192fecc-046d-4905-868f-b8200320309c</div>
<div>Version: 1</div>
<div>Effective Time: 20100930</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
